
A correct enzalutamide order depends on more than selecting 40 mg, 80 mg or 160 mg on a quotation. You need to match the product to the patient population, approved dosage form, interaction profile, destination-market rules, shipment conditions and batch documentation before committing funds or stock.
Key takeaways
- Match the strength and dosage form to the destination-country label.
- Screen seizure risk, cardiovascular history and CYP-mediated medicine interactions.
- Request batch records, expiry details, certificates and destination-market authorisation evidence.
- Quarantine shipments with broken seals, missing data or unexplained temperature excursions.
Match the order to the prostate-cancer indication and labelled regimen
Procure enzalutamide only for a documented treatment decision in which local guidelines and the destination-country label permit its indication, strength and dosage form. Metastatic castration-sensitive prostate cancer means metastatic disease that remains responsive to androgen deprivation; metastatic castration-resistant prostate cancer means progression despite castrate testosterone levels.
| Clinical setting | Procurement decision | Treatment relationship |
|---|---|---|
| Metastatic castration-sensitive prostate cancer | Confirm guideline and label eligibility | Use with ongoing androgen-deprivation therapy (ADT), unless surgical castration provides androgen suppression |
| Metastatic castration-resistant prostate cancer | Confirm progression despite castration and label eligibility | Continue ADT unless the patient has undergone orchiectomy |
| Abiraterone, apalutamide, darolutamide, chemotherapy or radioligand treatment | Do not substitute automatically | Each has different indications, monitoring, contraindications and administration requirements |
Specify “enzalutamide 160 mg daily dose,” the exact strength and the registered form. The usual adult regimen is 160 mg orally once daily, with or without food. The patient must swallow each unit whole; do not open, chew, dissolve, crush or split capsules or tablets unless the approved product information expressly allows it.
For a missed dose, take it when remembered on the same day; if the entire day is missed, resume the normal dose the next day and do not double it. After vomiting, do not take an extra dose; take the next dose at the usual time, following the supplied label.
Screen safety risks and medicine interactions before releasing stock
1. Preserve the oncology service’s current clinical record before releasing stock: prior seizure, brain injury, stroke, brain metastases, medicines that lower the seizure threshold, falls or fractures, hypertension, ischaemic heart disease and liver impairment. Seizure risk is material, and falls or fractures can worsen in older men with treatment-related bone loss.
2. Record every prescribed, over-the-counter and complementary medicine. Enzalutamide causes strong CYP3A4 induction and moderate CYP2C9 and CYP2C19 induction, which can lower exposure to warfarin, some antiepileptics, oral anticoagulants, immunosuppressants, hormonal contraceptives and other narrow-therapeutic-index medicines. This enzalutamide drug interactions review belongs in the supply record, not only in the dispensing file.
3. Check for strong CYP2C8 inhibitors, which can raise enzalutamide exposure, and strong CYP3A4 inducers, which can reduce it. Avoid these combinations where the label says to do so; if unavoidable, apply the supplying product’s exact dose-adjustment label rather than copying a dose from another brand or market.
Document the CYP2C9 and CYP2C19 medication interactions for medicines requiring therapeutic monitoring.
4. Attach the approved patient materials. Women who are pregnant or may become pregnant must not handle damaged or opened capsules or tablets without protective precautions. Male patients need the label’s contraception instructions during treatment and for the specified period after the last dose; preserve that exact post-treatment interval.
Quarantine damaged units and do not release them.
Compare dosage forms, pack economics and transport conditions correctly
A 160 mg daily regimen does not automatically mean one 160 mg unit. It may require four enzalutamide 40 mg capsules or two enzalutamide 80 mg tablets.
Write the exact form on the purchase order: “enzalutamide 40 mg soft capsule” or “enzalutamide 80 mg film-coated tablet”; name a 160 mg unit only when the destination regulator accepts that presentation.
| Presentation | Unit calculation | Pack comparison |
|---|---|---|
| Enzalutamide 40 mg soft capsules | 4 units daily for 160 mg | Record capsules per pack, treatment days and approved enzalutamide pack size |
| Enzalutamide 80 mg film-coated tablets | 2 units daily for 160 mg | Record tablets per pack, treatment days and approved enzalutamide pack size |
| 160 mg unit | 1 unit daily only if authorised | Confirm dosage form, pack count and destination-market registration |
Compare total daily dose, not strength alone. Calculate cost per treatment day from the complete pack price and usable units, then check remaining shelf life against treatment days, dispensing intervals and minimum stock policy. A lower unit price can become waste if the pack expires before use or its size does not match the regimen.
Keep stock in its original, sealed container for batch and manufacturer traceability, moisture protection and tamper evidence. Apply FEFO rotation. Enzalutamide storage temperature is commonly 20–25 °C, with permitted excursions of 15–30 °C under the product label.
Nagpur export lanes still need protection from heat, humidity, direct light and recorded excursions; no refrigerated cold chain does not mean uncontrolled transport.
Verify destination-market authorisation and build the export document pack
Before accepting a Nagpur-origin enzalutamide shipment, verify that the exact brand and manufacturer are lawful for sale in the destination market—not merely exportable from India.
| Check | Evidence to confirm | Failure consequence |
|---|---|---|
| Brand and manufacturer | Destination marketing authorisation and approved manufacturer name | The shipment may be unauthorised |
| Indication and form | Enzalutamide product registration covering the requested indication, strength and dosage form | The hospital cannot use the product under its approval |
| Import route | Valid import licence, prescription classification and regulator acceptance | Customs clearance will not create saleability |
| Buyer acceptance | Hospital formulary or tender approval, required language and local batch or serialisation rules | The consignee may reject compliant-looking stock |
Build the pack with:
- Commercial invoice, packing list and transport documents
- Certificate of analysis for the named batch
- Batch number, manufacturing date, expiry date and remaining-shelf-life evidence
- Manufacturer name, address and contact details
- Product-registration evidence and certificate of pharmaceutical product where required
- Export permit, import permit or other authority approval where required
An Indian IEC, invoice and airway bill prove an export transaction, not destination-market saleability. A certificate of analysis reports test results for one batch; it does not authenticate physical stock, prove distribution rights or replace packaging inspection and manufacturer confirmation.
For global oncology medicine procurement, ask Cordium Pharmaceuticals Pvt Ltd which documents it can supply, which the manufacturer must issue and which the importer or consignee must obtain for the enzalutamide export from Nagpur.
Related products
![]() | Oncology Medicine Obnyx Capsules 40mg, 80mg & 160mg – Enzalutamide Capsules in India Obnyx Capsules contain enzalutamide, an androgen receptor inhibitor used in the treatment of advanced prostate cancer. View product → |
![]() | Oncology Medicine Uses & Side Effects Capmide Capsules 40mg, 80mg & 160mg Capmide Capsules are associated with enzalutamide, a prescription medicine used in the treatment of prostate cancer. |
Control batch integrity, security and receipt after dispatch
Treat each shipment as a controlled asset from dispatch, not as ordinary tablet freight. Pharmaceutical export quality control starts with tamper-evident original packaging, documented custody and a release record that links every carton to its enzalutamide batch verification.
1. Record the batch number, expiry date, shipped quantity and serialised identifiers where applicable. Use batch-level or serialised inventory records, restrict warehouse and loading access, and apply FEFO pharmaceutical inventory rotation so the shortest-dated acceptable stock moves first.
2. Keep units in the manufacturer’s moisture- and tamper-protective container. Document temperature monitoring for medicines during storage and transit, targeting 20–25 °C with permitted excursions of 15–30 °C where the approved label allows them. Protect cartons from heat, humidity and direct light; no refrigerated cold chain does not mean uncontrolled transport.
3. Move the consignment from Nagpur to the international gateway in a sealed, trackable vehicle with named handover points, access records and an incident log. Repacking into unvalidated bulk containers can damage stability, obscure identification and break the evidence needed for a targeted recall.
4. At receipt, reconcile the invoice, packing list, shipped quantity, batch number, expiry date and seal condition. Inspect every carton for moisture, heat damage, broken seals, altered labels or signs of repacking.
Request manufacturer confirmation when stock, the certificate or chain of custody is unclear; a certificate of analysis alone proves neither physical authenticity nor distribution rights.
Quarantine every discrepancy and resolve it before a hospital, wholesaler or tender supply accepts the batch.
Frequently asked questions
How do you match an enzalutamide order to the patient’s treatment?
Confirm the documented prostate-cancer indication, castration status, destination-country label, prescribed strength and dosage form before releasing stock.
Which safety checks matter before supplying enzalutamide?
Review seizure risk, cardiovascular history and concurrent medicines for interactions, including medicines affected by enzalutamide’s enzyme-inducing effects.
How should you compare enzalutamide dosage forms, packs and transport requirements?
Compare the prescribed formulation, total dose, units per pack, remaining shelf life and manufacturer’s labelled storage and transport conditions.
Which documents support an international enzalutamide shipment?
Assemble the commercial invoice, packing list, batch and expiry details, certificate of analysis, certificate of origin, export documents and destination-market authorisation evidence.
Related products
![]() | Oncology Medicine Azel Capsules – Enzalutamide Capsules Product Specification Azel Capsules contain enzalutamide, an androgen receptor inhibitor used in the treatment of prostate cancer in adult men. |
![]() | Oncology Medicine Enzalutamide Capsules – Product Description, Uses, Dosage & FAQs Enzalutamide capsules are prescription medicines used as part of the treatment of certain types of advanced prostate cancer. |
![]() | Oncology Medicine BDEnza Capsules (Enzalutamide) – Information for Patients in Dubai, UAE BDEnza Capsules contain enzalutamide, an oral anti-androgen medicine used under specialist medical supervision for the treatment of prostate cancer. |











